Moderna launches first human trial of Bundibugyo Ebola vaccine

• The Bundibugyo strain is driving the world's largest Ebola outbreak on record in the Democratic Republic of Congo, with 3,748 confirmed cases and 1,657 deaths as of August 1, with cases increasing faster than previous outbreaks
• The experimental vaccine (mRNA-1469) uses the same mRNA technology as Moderna's COVID-19 vaccine and is being tested at three sites in Canada with Health Canada clearance
• If approved, Moderna plans to make at least 500,000 doses available to low- and middle-income countries at access pricing under its CEPI partnership agreement

Summary: Moderna Launches First Human Trial of Bundibugyo Ebola Vaccine

Key Development:

Moderna has initiated its first human trial of mRNA-1469, an experimental vaccine targeting Bundibugyo ebolavirus, a deadly Ebola strain with no currently approved vaccine. Health Canada has cleared the early-stage study, and first volunteers have already been dosed.

Trial Specifications:

• Enrollment target: approximately 80 healthy adults across three Canadian sites
• Primary objective: assess safety and immune response
• Technology: utilizes same mRNA platform as Moderna's COVID-19 vaccine

Financial Details:

The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged up to $50 million to support early testing and manufacturing. If approved, Moderna commits to providing at least 500,000 doses to low- and middle-income countries at access pricing under the CEPI agreement.

Disease Impact:

The Bundibugyo strain is driving an outbreak in the Democratic Republic of Congo that has become the world's deadliest Ebola outbreak on record:

• 3,748 confirmed cases
• 1,657 confirmed deaths (as of August 1)
• More than 1,650 total fatalities
• Cases increasing faster than the previous largest outbreak

Market Context:

Both the World Health Organization and Africa CDC have declared the current outbreak a public health emergency. CEPI's chief executive noted the acceleration rate exceeds historical precedents, underlining urgency for vaccine development.

Implications:

Success could expand Moderna's mRNA vaccine portfolio beyond COVID-19, demonstrating platform versatility for emerging infectious diseases while addressing a critical global health need. The trial represents a strategic partnership model combining public health funding with commercial pharmaceutical development capabilities.